You are currently viewing Pepticom’s AI Discovered 53 Novel Immune-Mmodulators
Pepticom's image on the cover of the Journal of Immunology's December issue.

Pepticom was honored with an image from their article on this December’s Journal of Immunology.

The image is taken from Pepticom’s latest article “Computationally Designed Bispecific MD2/CD14 Binding Peptides Show TLR4 Agonist Activity”.

link to the article:

Finding the right molecule to cure disease is critical for patients. However, the number of molecules (drug candidates) exceeds the number of stars in our universe, making the search task extremely difficult. Pepticom introduced the world’s first Artificial Intelligence (AI) platform for peptide-drug discovery. Just as Google disrupted information search, Pepticom is transforming the way drug candidates are discovered, finding solutions that would otherwise be missed.

In this game changing article, Pepticom’s AI discovered 53 novel immune-modulators, strengthening the effort to fight complex diseases, such as cancer by modifying the patient’s own immune response. These never seen before, diverse set of molecules were discovered in a record breaking time and costs, demonstrating the true power of AI and its ability to transform pharma R&D.

About Pepticom

Pepticom is an artificial intelligence company seeking to discover novel molecules in the pharmaceutical and agricultural markets. The algorithmic platform combines principles from economic and molecular mechanics to generate a wide scope of active molecules with higher success rates. In so doing, Pepticom aims to lower the number of R&D candidates synthesized and tested with a similar reduction in time and costs when compared with traditional lab-based discovery methods.

The use of computational technology allows Pepticom to address complex targets unreachable by laboratory methods and to further enhance R&D. The platform utilizes the structure of the target protein to design innovative peptides at atomic resolution. It is capable of designing several types of peptides including linear, helical, cyclic, and D-amino acid peptides.

The company is involved in various successful discovery projects – ranging from uses in agriculture to immune-modulators, diabetes, and Alzheimer’s disease – and has several molecules in different R&D stages.